West Pharmaceutical Services (WST) 2025 Earnings Quality Report

Grade: A — Strong Financial Health

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-17) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 Critical Audit Matter on Provision for Income Taxes)

One-line verdict: West Pharmaceutical Services is the cleanest report in our 2025 healthcare screening universe. Net sales grew 6.3% to $3.07B (4.3% excluding FX), net income was essentially flat at $493.7M, and operating cash flow jumped $101M to $754.8M — a 14% swing that management attributes to "improved operating results and the timing of incentive payments." Free cash flow of $542M covers net income 1.10x. The balance sheet has $791M of cash against only $203M of debt — a 3.9x cash coverage ratio that is the inverse of the leveraged healthcare peer group. Goodwill plus intangibles is a modest slice of the $3.18B equity base. The only screening watch is D4 (write-offs up 1,400% YoY), which traces to a single $8.4M charge for the SmartDose 3.5mL product line sale to AbbVie and a $4.5M cost-method investment impairment — both clearly disclosed, non-recurring, and small. The Beneish M-Score of -2.79 and F-Score of 0.24 (0.11% probability of manipulation) are the best scores of any ticker in our 2025 screening batch. Altman Z-Score of 9.37 is a comfortable safe zone. This is a quality operator with a quality balance sheet.

Two Segments, Injectable Drug Containment Leadership

Per the MD&A: "We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world."

Segment results per the Net Sales table:

Per the MD&A: "Consolidated net sales increased by $180.9 million, or 6.3%, in 2025, including a favorable foreign currency translation impact of $56.4 million. Excluding foreign currency translation effects, consolidated net sales increased by $124.5 million, or 4.3%."

Proprietary Products growth came from "an increase in sales of Westar, NovaChoice and Envision products." These are the premium elastomer closure and integrated drug containment systems used in biologics manufacturing. Contract-Manufactured Products growth was "primarily due to an increase in sales of self-injection devices for obesity and diabetes" — West is a key supplier to the GLP-1 auto-injector supply chain, partially offset by "a decrease in sales of healthcare diagnostic devices."

Gross Margins: Proprietary Products Rebounded 1.9 Points

Per the MD&A: "Proprietary Products gross profit margin increased by 1.9 margin points in 2025. The increase is due to increased customer demand, primarily of high value components, higher plant absorption and sales price increases. These increases were partially offset by approximately $47 million in customer incentives received in connection with volumes achieved during 2024 that were not repeated in 2025."

The 1.9 point gross margin recovery in Proprietary Products is the key operational story: 2024 was a destocking trough, and 2025 saw customers work back through inventory and return to normal ordering patterns. The $47M in customer volume incentives not repeated in 2025 was a headwind that gross margin absorbed easily.

Results of Operations: Flat Net Income Despite Growth

Per the MD&A GAAP-to-adjusted reconciliation table:

And the adjusted (non-GAAP) versions:

2025 adjusted EPS of $7.29 vs. 2024 adjusted EPS of $6.75 = +8% — the cleaner operational result. GAAP net income was roughly flat because of $37.5M in 2025 unallocated items:

Per the MD&A: "During 2025, the Company recorded pre-tax charges of $23.3 million related to our two existing restructuring programs: (i) $18.4 million within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $4.9 million within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries."

On SmartDose: "During 2025, the Company recorded charges of $8.4 million related to the Company's agreement to sell its SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie."

Cash Flow: The Highlight of the Report

Per the MD&A Liquidity section:

Operating cash flow rebounded $101.4M to $754.8M — per the MD&A "due primarily to improved operating results and the timing of incentive payments." Investing activities used $92.8M less cash "due primarily to a decrease in capital expenditures" — the new North Carolina facility is online and 2022-2023 capex buildout has normalized. Financing activities used $437.5M less "due primarily to a decrease in purchases under our share repurchase programs."

CFFO at 1.53x net income. FCF at 1.10x net income. These are the cleanest cash conversion metrics in our 2025 screening universe. Virtually every dollar of reported earnings came in as cash, and every dollar was available for shareholder return or reinvestment.

Balance Sheet: The Opposite of Levered

Per the Liquidity and Capital Resources table in MD&A:

Cash of $791M is 3.9x total debt of $203M. The inverse of every other healthcare company we screened. Per the MD&A: "At December 31, 2025, we had no outstanding borrowings under the multi-currency revolving credit facility. At December 31, 2025, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.3 million, was $497.7 million. We do not expect any significant limitations on our ability to access this source of funds."

Working capital grew from $988M to $1,323M. Inventories increased $67M to support expected 2026 demand. Accounts receivable grew only 4% ($22M) on 6.3% revenue growth — the DSO trajectory is slightly improving.

The $56M cash increase plus $494M net income vs $755M CFFO means the working capital / non-cash adjustments bridged $261M — dominated by depreciation ($176M) and the absence of 2024's incentive compensation payout.

The Single Watch Flag: D4

The screening engine flagged D4 as a watch: "Write-offs up 1400% YoY." This traces to:

Combined $12.9M against 2024's ~$1M baseline produces the 1,400% year-over-year jump. Both items are explicitly disclosed in the MD&A's reconciliation table, both are individually small (0.4% of net income), and neither indicates underlying asset quality deterioration. This is the definition of a false positive watch flag.

The 18-Point Screening

Beneish M-Score components:

All components benign. The combination of near-unity CFFO/NI, clean accruals, gross margin improvement, and no balance sheet expansion produces an M-Score of -2.79 — low manipulation probability.

F-Score of 0.24 implies 0.11% probability of manipulation — the lowest in our 2025 healthcare screening batch.

Key Risks from the 10-K

1. Global Economic Conditions and Customer Destocking

Per Item 1A Risk Factors: "Global economic conditions, including inflation and supply chain disruptions, could adversely affect our operations. General global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, may result in unfavorable conditions. Those conditions could negatively affect demand for our products due to customers decreasing their inventories in the near-term or long-term."

2024 was a destocking year. 2025 was the rebound. Another destocking cycle is the primary macro risk.

2. Tariffs and International Operations

Per the MD&A: "In recent months, the U.S. government has imposed additional tariffs and trade restrictions on certain goods produced outside of the United States. In response to these actions, certain jurisdictions in which we operate have imposed or are considering imposing tariffs and restrictions on certain goods produced in the United States. We continue to monitor this dynamic situation to assess the impact of these tariffs on our business and actions we can take to minimize their impact. Based on the information available at this time, the impact was not material to our 2025 results."

Per Item 1A: "A significant portion of our net sales and earnings are generated internationally. Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025... In addition, many of our manufacturing facilities and suppliers are located outside of the U.S."

3. Cybersecurity

Per Item 1A: "Unauthorized access to our or our customers information and systems could negatively impact our business. Our systems and networks, as well as those of our customers, suppliers, service providers, and banks, have and may in the future become the target of cyberattacks or information security breaches."

4. Customer Concentration in Injectable Drugs

West's Proprietary Products revenue depends heavily on a small set of large pharma customers producing biologics and self-administered injectables. Any major customer loss or a shift in drug delivery format (e.g., oral GLP-1 success at the expense of injectables) could meaningfully impact Westar/NovaChoice volume.

5. Quality and Regulatory Compliance

West's closures and delivery systems are the primary container seal between the drug and the patient. Any quality failure — contamination, particulates, elastomer defects — could trigger customer drug recalls, FDA actions, and litigation.

6. Foreign Currency Risk

2025 FX benefited net sales by $56.4M. A reversal would erase much of the reported growth.

Auditor's Critical Audit Matter: Provision for Income Taxes

From PwC's report: "Provision for Income Taxes. As described in Notes 1 and 17 to the consolidated financial statements, the Company's consolidated deferred tax assets were $114.[truncated]..." PwC selected income tax complexity — particularly deferred tax assets and the ongoing legal structure optimization — as its Critical Audit Matter. This is not an operational concern; it is the natural CAM for a multinational undertaking a legal structure reorganization. The 2024 plan (mentioned in MD&A) to "optimize the legal structure of the Company and its subsidiaries" naturally creates deferred tax complexity that draws auditor attention.

Key Financial Trends (3-Year)

Summary

Grade: A. The only A grade in our 2025 healthcare sector screening batch.

West Pharmaceutical Services passes 17 of 18 checks with a single watch flag that is a clearly explained one-time item (SmartDose product sale + cost-method investment impairment totaling $12.9M against prior-year baseline of roughly nothing).

What the numbers show:

West is structurally positioned in injectable drug containment — an industry where quality failure means existential risk to customers, so switching costs are enormous and margins reflect the value captured. The GLP-1 boom in auto-injector self-administration is an organic tailwind to the Contract-Manufactured Products segment.

What to watch:

The grade is earned. West Pharmaceutical Services reports earnings that match cash flow, maintains a fortress balance sheet, and shows no sign of the manipulation patterns that trip the screening framework. In a healthcare universe where most of our 2025 screens produced F grades, WST's A grade reflects clean fundamentals rather than low bar grading.

**Disclaimer**: This report is based on West Pharmaceutical Services' fiscal year 2025 10-K filed with the SEC on February 17, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade A means strong financial health across all 18 checks.